#Accelerationism It showed 58 percent efficacy against symptomatic disease in its Phase 3 clinical trial. That is a lower number than in initial Pfizer and Moderna trials but “in line with expected vaccine effectiveness in today’s environment dominated by variants of concern,” Sanofi and GSK said in a statement. The companies also said that the new shot could be an effective booster. When used as an extra dose after one of the other available coronavirus vaccines, it increased antibody levels by 18- to 30-fold. The vaccine was safe and well tolerated by adults of all ages, the companies said. The data has not yet been published.
top of page
bottom of page